McGlone Suttner Wealth Management Inc. Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

McGlone Suttner Wealth Management Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 20.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,239 shares of the biopharmaceutical company’s stock after selling 3,139 shares during the quarter. McGlone Suttner Wealth Management Inc.’s holdings in Pfizer were worth $325,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cornerstone Wealth Management LLC raised its holdings in shares of Pfizer by 5.7% during the fourth quarter. Cornerstone Wealth Management LLC now owns 82,391 shares of the biopharmaceutical company’s stock worth $2,186,000 after purchasing an additional 4,479 shares during the period. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Hengehold Capital Management LLC grew its position in Pfizer by 1.7% in the 4th quarter. Hengehold Capital Management LLC now owns 119,846 shares of the biopharmaceutical company’s stock valued at $3,180,000 after buying an additional 2,043 shares in the last quarter. Secure Asset Management LLC raised its holdings in Pfizer by 32.0% during the fourth quarter. Secure Asset Management LLC now owns 87,874 shares of the biopharmaceutical company’s stock worth $2,331,000 after purchasing an additional 21,294 shares in the last quarter. Finally, Teamwork Financial Advisors LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $1,204,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PFE shares. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Up 1.7 %

Shares of NYSE:PFE opened at $26.46 on Friday. The company has a market capitalization of $149.94 billion, a PE ratio of 35.75, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a fifty day moving average of $26.07 and a 200-day moving average of $27.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The firm’s revenue was up 31.2% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.50%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.